文献速递慢性静脉疾病

编辑精选——上腔静脉、锁骨下静脉及头臂静脉狭窄腔内支架置入术后24个月通畅率的系统评价与Meta分析

Editor's Choice - A Systematic Review and Meta-analysis of 24 Month Patency After Endovenous Stenting of Superior Vena Cava, Subclavian, and Brachiocephalic Vein Stenosis.
PubMed 文献 · Eur J Vasc Endovasc Surg · 2024-07-06

该系统评价与Meta分析纳入39项研究共1539例上腔静脉、锁骨下静脉及头臂静脉狭窄支架置入患者,评估技术成功率及不同时间点的一期、一期辅助和二期通畅率。术后1年内一期通畅率为81.5%(95%CI 74.5-86.9%),12-24个月降至63.2%(95%CI 51.9-73.1%);≥24个月一期辅助通畅率和二期通畅率分别为72.7%(95%CI 49.1-88.0%)和76.6%(95%CI 51.1-91.1%)。恶性狭窄患者1-3个月和12-24个月的一期通畅率显著高于良性狭窄,但二期通畅率两组无显著差异;GRADE证据确定性均为极低。

要点

  • 术后1年内一期通畅率为81.5%(95%CI 74.5-86.9%),12-24个月降至63.2%(95%CI 51.9-73.1%)。
  • ≥24个月一期辅助通畅率和二期通畅率分别为72.7%(95%CI 49.1-88.0%)和76.6%(95%CI 51.1-91.1%)。
  • 恶性狭窄患者1-3个月和12-24个月一期通畅率显著高于良性狭窄,二期通畅率两组无显著差异。

核心结论

  • 支架置入是治疗上腔静脉、锁骨下静脉及头臂静脉良恶性狭窄的有效干预措施。
  • 术后1年内一期通畅率良好,6-12个月时81.5%的支架保持通畅。
  • 术后1年后通畅率下降,12-24个月一期通畅率为63.2%、二期通畅率为89.3%,提示再干预后结局改善。
  • 缺乏高质量证据,需要更多研究探讨通畅率结局及监测或再干预计划的必要性。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Scopus和Cochrane Library数据库截至2022年12月的研究。
  • 共纳入39项研究,报告1539例患者的结局。
  • 采用GRADE评估证据确定性。

主要发现

  • 术后1年内一期通畅率为81.5%(95%CI 74.5-86.9%)。
  • 12-24个月一期通畅率降至63.2%(95%CI 51.9-73.1%)。
  • ≥24个月一期辅助通畅率为72.7%(95%CI 49.1-88.0%),二期通畅率为76.6%(95%CI 51.1-91.1%)。
  • 亚组分析显示,恶性狭窄患者1-3个月和12-24个月的一期通畅率显著高于良性狭窄患者。
  • 恶性与良性亚组的汇总二期通畅率无显著差异。

关键数值与推荐

  • GRADE分析确定所有结局的证据确定性均为极低。

局限性

  • GRADE分析确定所有结局的证据确定性均为极低。
  • 缺乏高质量证据。
  • 需要更多研究探讨通畅率结局及监测或再干预计划的必要性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: This systematic review and meta-analysis aimed to appraise recent evidence assessing patency outcomes at various time points in patients with superior vena cava, subclavian, and brachiocephalic vein stenosis who had undergone stenting. DATA SOURCES: PubMed, Scopus, and Cochrane Library databases were searched for studies up to December 2022. REVIEW METHODS: Measured outcomes included technical success rate, primary, primary assisted, and secondary patency at various time points. A subgroup analysis was also conducted to compare malignant and benign obstruction. GRADE was used to assess the certainty of evidence. RESULTS: Thirty nine studies reporting outcomes in 1 539 patients were included in the meta-analysis. Primary patency up to one year after the procedure was 81.5% (95% CI 74.5 - 86.9%). Primary patency declined after one year to 63.2% (95% CI 51.9 - 73.1%) at 12 - 24 months. Primary assisted patency and secondary patency at ≥ 24 months were 72.7% (95% CI 49.1 - 88.0%) and 76.6% (95% CI 51.1 - 91.1%). In the subgroup analysis, primary patency was significantly higher in patients with a malignant stenosis compared with a benign stenosis at 1 - 3 and 12 - 24 months. No significant difference was seen for pooled secondary patency rates when comparing the malignant and benign subgroups. GRADE analysis determined the certainty of evidence for all outcomes to be very low. CONCLUSION: Stenting is an effective intervention for benign and malignant stenosis of the superior vena cava, subclavian, and brachiocephalic veins. Primary patency rates were good up to one year after the procedure, with 81.5% of stents retaining patency at 6 - 12 months. Patency rates declined after one year, to 63.2% primary and 89.3% secondary patency at 12 - 24 months, showing improved outcomes following re-intervention. High quality evidence is lacking. More research is needed to investigate patency outcomes and the need for surveillance or re-intervention programs.

来源:Eur J Vasc Endovasc Surg,查看原文。版权归原作者所有。

引用

  1. Chawla S, Zhang Q, Gwozdz AM, et al. Editor's Choice - A Systematic Review and Meta-analysis of 24 Month Patency After Endovenous Stenting of Superior Vena Cava, Subclavian, and Brachiocephalic Vein Stenosis. Eur J Vasc Endovasc Surg. 2024. PMID: 38977059. doi:10.1016/j.ejvs.2024.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。